NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,391 | +20.0% | 148 | +208.3% | 0.00% | – |
| Q2 2023 | $1,992 | -82.2% | 48 | -74.2% | 0.00% | -100.0% |
| Q1 2023 | $11,187 | -42.9% | 186 | -30.3% | 0.00% | -50.0% |
| Q4 2022 | $19,584 | -34.7% | 267 | -32.2% | 0.00% | -50.0% |
| Q3 2022 | $30,000 | -3.2% | 394 | -12.4% | 0.00% | 0.0% |
| Q2 2022 | $31,000 | -38.0% | 450 | -25.1% | 0.00% | -33.3% |
| Q1 2022 | $50,000 | +212.5% | 601 | +175.7% | 0.01% | +200.0% |
| Q4 2021 | $16,000 | +166.7% | 218 | +327.5% | 0.00% | +100.0% |
| Q3 2021 | $6,000 | -81.8% | 51 | -65.3% | 0.00% | -80.0% |
| Q2 2021 | $33,000 | +230.0% | 147 | +104.2% | 0.01% | +150.0% |
| Q1 2021 | $10,000 | +900.0% | 72 | +928.6% | 0.00% | – |
| Q4 2020 | $1,000 | – | 7 | +75.0% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 4 | -94.7% | 0.00% | -100.0% |
| Q3 2019 | $5,000 | – | 76 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |